CSIR-IICT Ties Up with Cipla to Develop Anti-COVID-19 Drug
: Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has tied up with pharmaceutical giant Cipla to work on development of anti- viral drugs to contain COVID-19.
Hyderabad, Mar 17 (PTI): Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has tied up with pharmaceutical giant Cipla to work on development of anti- viral drugs to contain COVID-19.
Research on anti-viral drugs has been on throughout the world for long and many companies have developed molecules having anti-viral properties. But due to lack of demand, these molecules were not widely marketed, according to IICT sources.
However, the CSIR-IICT decided to work on three such molecules -- remdesivir, favipiravir and baloxavir. Cipla urged the IICT director S Chandrasekhar to start work on these molecules on an immediate basis.
Quoting a top official of Cipla, the sources said Cipla would upscale the process on the basis of know-how given by CSIR-IICT.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)